sellWeak cluster of 510b5-1 plan
Henry E. Pelish sold $1.3M of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 14,205 shares at an average of $90.04, traded Oct 15, 2025, filed Oct 17, 2025.
Warning score
25Value
$1.3M
14,205 shares
Holdings after
65,963
-18% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$1.3M at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-242567, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +3,668 | $18.93 | $69k | 69,631 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +7,495 | $27.85 | $209k | 77,126 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +3,042 | $72.35 | $220k | 80,168 | Oct 17, 2025 |
| Oct 15, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -14,205 | $90.04 | $1.3M | 65,963 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,668 | $0.00 | $0 | 10,569 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,495 | $0.00 | $0 | 13,156 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,042 | $0.00 | $0 | 24,058 | Oct 17, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.